drugset
drugset / Trial / NCT05732272

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

NCT05732272 ↗

Phase 3 Recruiting 500 enrolled University of Kansas Medical Center
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.

Timeline

Start
2023-02-28
Primary completion
2027-01-31
Completion
2027-04-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupropion Small molecule 150 mg —

Indications

No indication recorded.